345 related articles for article (PubMed ID: 18238737)
1. Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease.
Andress DL; Coyne DW; Kalantar-Zadeh K; Molitch ME; Zangeneh F; Sprague SM
Endocr Pract; 2008; 14(1):18-27. PubMed ID: 18238737
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
Joy MS; Karagiannis PC; Peyerl FW
J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
Sharma A; Marshall TS; Khan SS; Johns B
Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D analogues for the management of secondary hyperparathyroidism.
Martin KJ; González EA
Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
[TBL] [Abstract][Full Text] [Related]
5. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
[TBL] [Abstract][Full Text] [Related]
6. Interventions for metabolic bone disease in children with chronic kidney disease.
Hahn D; Hodson EM; Craig JC
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD008327. PubMed ID: 26561037
[TBL] [Abstract][Full Text] [Related]
7. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
9. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
10. Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the "U".
Cozzolino M; Brandenburg V
Clin Nephrol; 2009 Jun; 71(6):593-601. PubMed ID: 19473626
[TBL] [Abstract][Full Text] [Related]
11. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
12. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study.
Ketteler M; Martin KJ; Wolf M; Amdahl M; Cozzolino M; Goldsmith D; Sharma A; Marx S; Khan S
Nephrol Dial Transplant; 2012 Aug; 27(8):3270-8. PubMed ID: 22387567
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study.
Roggeri DP; Mazzaferro S; Brancaccio D; Cannella G; Messa P; Di Luca M; Morosetti M; Costanzo AM; di Luzio Paparatti U; Cornago D; Cozzolino M;
J Med Econ; 2012; 15(6):1110-7. PubMed ID: 22702445
[TBL] [Abstract][Full Text] [Related]
14. Current treatment options for secondary hyperparathyroidism in patients with stage 3 to 4 chronic kidney disease and vitamin D deficiency.
Galassi A; Ciceri P; Porata G; Iatrino R; Boni Brivio G; Fasulo E; Magagnoli L; Stucchi A; Frittoli M; Cara A; Cozzolino M
Expert Opin Drug Saf; 2021 Nov; 20(11):1333-1349. PubMed ID: 33993809
[No Abstract] [Full Text] [Related]
15. Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol.
Cozzolino M; Galassi A; Gallieni M; Brancaccio D
Curr Vasc Pharmacol; 2008 Apr; 6(2):148-53. PubMed ID: 18393917
[TBL] [Abstract][Full Text] [Related]
16. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial.
Kovesdy CP; Lu JL; Malakauskas SM; Andress DL; Kalantar-Zadeh K; Ahmadzadeh S
Am J Kidney Dis; 2012 Jan; 59(1):58-66. PubMed ID: 21885174
[TBL] [Abstract][Full Text] [Related]
17. Low-dose cholecalciferol supplementation and dual vitamin D therapy in haemodialysis patients.
Dusilová-Sulková S; Šafránek R; Vávrová J; Horáček J; Pavlíková L; Palička V
Int Urol Nephrol; 2015 Jan; 47(1):169-76. PubMed ID: 25262147
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of secondary hyperparathyroidism in hemodialysed patients--paricalcitol with or without cinacalcet].
Zawierucha J; Małyszko J; Małyszko J; Dryl-Rydzyńska T; Prystacki T; Marcinkowski W
Przegl Lek; 2016; 73(4):229-32. PubMed ID: 27526425
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis.
Pérez-Ricart A; Galicia-Basart M; Alcalde-Rodrigo M; Segarra-Medrano A; Suñé-Negre JM; Montoro-Ronsano JB
PLoS One; 2016; 11(9):e0161527. PubMed ID: 27588942
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D in Chronic Kidney Disease and Dialysis Patients.
Jean G; Souberbielle JC; Chazot C
Nutrients; 2017 Mar; 9(4):. PubMed ID: 28346348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]